AU2006219717B2 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
AU2006219717B2
AU2006219717B2 AU2006219717A AU2006219717A AU2006219717B2 AU 2006219717 B2 AU2006219717 B2 AU 2006219717B2 AU 2006219717 A AU2006219717 A AU 2006219717A AU 2006219717 A AU2006219717 A AU 2006219717A AU 2006219717 B2 AU2006219717 B2 AU 2006219717B2
Authority
AU
Australia
Prior art keywords
composition according
microparticle
microparticle composition
microparticles
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006219717A
Other languages
English (en)
Other versions
AU2006219717A1 (en
Inventor
Stephen J. Elvin
James Edward Eyles
Gareth David Healey
Angela Westwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UK Secretary of State for Defence
Original Assignee
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0504276A external-priority patent/GB0504276D0/en
Priority claimed from GB0511801A external-priority patent/GB0511801D0/en
Application filed by UK Secretary of State for Defence filed Critical UK Secretary of State for Defence
Publication of AU2006219717A1 publication Critical patent/AU2006219717A1/en
Application granted granted Critical
Publication of AU2006219717B2 publication Critical patent/AU2006219717B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006219717A 2005-03-02 2006-03-02 Pharmaceutical composition Ceased AU2006219717B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0504276A GB0504276D0 (en) 2005-03-02 2005-03-02 Pharmaceutical composition
GB0511801.3 2005-03-02
GB0504276.7 2005-06-10
GB0511801A GB0511801D0 (en) 2005-06-10 2005-06-10 Pharmaceutical composition
PCT/GB2006/000751 WO2006092607A1 (en) 2005-03-02 2006-03-02 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
AU2006219717A1 AU2006219717A1 (en) 2006-09-08
AU2006219717B2 true AU2006219717B2 (en) 2009-05-21

Family

ID=36353665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006219717A Ceased AU2006219717B2 (en) 2005-03-02 2006-03-02 Pharmaceutical composition

Country Status (8)

Country Link
US (1) US20080138431A1 (enExample)
EP (1) EP1853227B1 (enExample)
JP (1) JP2008531672A (enExample)
AT (1) ATE438385T1 (enExample)
AU (1) AU2006219717B2 (enExample)
CA (1) CA2599329A1 (enExample)
DE (1) DE602006008278D1 (enExample)
WO (1) WO2006092607A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4846200B2 (ja) 2002-04-04 2011-12-28 コーリー ファーマシューティカル ゲーエムベーハー 免疫賦活性ｇ、ｕ含有オリゴリボヌクレオチド
EP2883957A1 (en) 2005-11-25 2015-06-17 Zoetis Belgium S.A. Immunostimmulatory oligoribonucleotides
AU2009241645B2 (en) * 2008-05-02 2014-07-17 Blink Therapeutics Limited Products and methods for stimulating an immune response
RS63817B1 (sr) 2010-07-06 2023-01-31 Glaxosmithkline Biologicals Sa Čestice za isporuku slične virionu za molekule samoreplicirajuće rnk
PT2590626E (pt) 2010-07-06 2016-01-26 Glaxosmithkline Biolog Sa Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
EP2591114B1 (en) 2010-07-06 2016-06-08 GlaxoSmithKline Biologicals SA Immunisation of large mammals with low doses of rna
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
HUE058361T2 (hu) 2010-08-31 2022-07-28 Glaxosmithkline Biologicals Sa Pegilált liposzómák immunogént kódoló RNA bejuttatására
ES2945135T3 (es) 2010-10-11 2023-06-28 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
BR0213119A (pt) * 2001-10-03 2004-12-28 Chiron Corp Composição imunogênica e uso da mesma
WO2004062599A2 (en) * 2003-01-06 2004-07-29 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
AU2004225480A1 (en) * 2003-03-26 2004-10-14 Multicell Immunotherapeutics, Inc. Selected RNA motifs to include cell death and/or apoptosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DIEBOLD et al. Science, American Association for the Advancement of Science. Vol.303: 1529-1531. 2004 *

Also Published As

Publication number Publication date
EP1853227A1 (en) 2007-11-14
WO2006092607A1 (en) 2006-09-08
CA2599329A1 (en) 2006-09-08
EP1853227B1 (en) 2009-08-05
US20080138431A1 (en) 2008-06-12
AU2006219717A1 (en) 2006-09-08
DE602006008278D1 (de) 2009-09-17
JP2008531672A (ja) 2008-08-14
ATE438385T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
Collier et al. Acetalated dextran microparticles for codelivery of STING and TLR7/8 agonists
JP6320912B2 (ja) 浸透圧媒介性放出合成ナノ担体
Joshi et al. Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses
Schlosser et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses
Joshi et al. Biodegradable particles as vaccine delivery systems: size matters
Diwan et al. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery
Singh et al. Charged polylactide co-glycolide microparticles as antigen delivery systems
CN101001646B (zh) 稳定化的合成免疫原投递系统
Zhang et al. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles
Heffernan et al. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly (inosinic acid)–poly (cytidylic acid)
EA030813B1 (ru) Способы генерации антительного иммунного ответа и увеличения местной индукции иммунных цитокинов при использовании синтетических наноносителей, соединенных с адъювантами
Goforth et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma
Zhang et al. A comparative study of the antigen‐specific immune response induced by co‐delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles
Liu et al. Encapsulation of Poly I: C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors
CN108324938B (zh) 一种颗粒型佐剂及其制备方法和应用
Joshi et al. Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride microparticles
EP2306993A1 (en) Protamine/rna nanoparticles for immunostimulation
AU2006219717B2 (en) Pharmaceutical composition
San Román et al. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology
WO2006035939A1 (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
Westwood et al. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid)
CN114404580A (zh) 一种树突状细胞癌症疫苗及其应用
CN1549728A (zh) 在可生物降解的微球体中含有抗原、基因载体和佐剂的免疫组合物
JP2006521321A (ja) 免疫応答を促進するためのミョウバンおよびＴｈ１免疫応答誘起アジュバントの使用
Perrie et al. Recent developments in particulate-based vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired